ChromaDex Co. (NASDAQ:CDXC) Short Interest Up 6.7% in January

ChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 31st total of 1,940,000 shares. Currently, 4.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 1.6 days.

Analyst Upgrades and Downgrades

CDXC has been the topic of several recent research reports. Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. StockNews.com downgraded shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Wednesday, January 15th. Finally, HC Wainwright raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, November 4th.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares of the company's stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 9.64% of the stock is owned by insiders.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently modified their holdings of CDXC. USA Financial Formulas acquired a new stake in ChromaDex during the fourth quarter worth approximately $25,000. Truist Financial Corp purchased a new position in shares of ChromaDex during the 4th quarter worth $54,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex during the second quarter worth $31,000. FMR LLC purchased a new stake in shares of ChromaDex in the third quarter valued at $55,000. Finally, SG Americas Securities LLC acquired a new position in ChromaDex in the third quarter valued at $61,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Stock Performance

ChromaDex stock traded down $0.17 during midday trading on Friday, reaching $5.52. 233,605 shares of the company were exchanged, compared to its average volume of 330,792. The firm's 50-day simple moving average is $5.91 and its 200-day simple moving average is $4.74. ChromaDex has a 1 year low of $1.46 and a 1 year high of $7.97. The company has a market capitalization of $421.62 million, a price-to-earnings ratio of 552.55 and a beta of 2.21.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.